Market Snapshot

S&P Futures
4,141.75
Dow Futures
33,071.00
NASDAQ Futures
14,017.75

5.90$-0.23 -3.75%
Market open    13:38:14 pm   
From: To:

Stock Snapshot

5.90
Prev. Close
6.06
Open
440.08M
Market Cap
10.59M
Number of Shares
5.90
Day Low
6.14
Day High
5.90
-
P/E Ratio
63.54M
Free Float in %
-0.76
EPS 2021
1.65
Book Value per Share
-
Cash Flow per Share
Fluidigm Corporation (FLDM)
Fluidigm Corporation (FLDM) stock rallied over -3.75% intraday to trade at $5.90 per share on NASDAQ. The stock opened with a gain of 2.71% at $6.06 and touched an intraday high of $6.14, rising 4.07% against the last close of $5.90. The stock went to a low of $5.90 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-06-18$6.06$5.90$5.90$6.14$5.901,900,412
2021-06-17$6.03$6.13$6.13$6.23$6.03744,900
2021-06-16$6.01$6.08$6.08$6.15$5.94604,300
2021-06-15$6.09$6.12$6.12$6.19$6.02699,000
2021-06-14$6.13$6.12$6.12$6.20$6.00736,100
2021-06-11$6.10$6.10$6.10$6.18$6.00772,100
2021-06-10$5.92$6.07$6.07$6.15$5.861,315,100
2021-06-09$5.66$5.90$5.90$6.03$5.622,764,400
2021-06-08$5.70$5.60$5.60$5.78$5.51788,600
2021-06-07$5.45$5.63$5.63$5.69$5.45523,800
2021-06-04$5.48$5.47$5.47$5.56$5.41543,500
Fluidigm Corporation
2 Tower Place
Suite 2000
South San Francisco, CA 94080
United States

http://www.fluidigm.com
650 266 6000
Employees
627
Sector
Healthcare
Sales or Revenue
Industry
Diagnostics & Research
5Y Sales Change
3.80
Fiscal Year Ends
2020-12-30
Mr. Stephen Christopher Linthwaite
Pres, CEO & Director
Mr. Vikram Jog
Chief Financial Officer
Mr. Bradley Allen Kreger
Sr. VP of Global Operations
Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.